Dr Bruce Burlington joins AZ board
AstraZeneca has appointed former FDA staffer Dr Bruce Burlington to its board as a non-executive director.
Dr Burlington spent 17 years with the FDA, serving as director of the US regulator’s Center for Devices and Radiological Health for six years in the 1990s as well as holding a number of senior roles in the Center for Drug Evaluation and Research.
Following this he moved into the pharma industry, serving in a series of senior executive positions at Wyeth (now part of Pfizer).
These included executive VP of business practices and compliance, executive VP of quality, regulatory, safety, compliance and audit, and senior VP of regulatory affairs and quality.
Dr Burlington is currently a pharmaceutical product development and regulatory affairs consultant, a non-executive director of Cangene Corporation and a member of the scientific advisory boards of the International Medica Foundation and Lundbeck.
AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, …
AstraZeneca and Daiichi Sankyo have announced results from the primary analysis of the DESTINY-Lung02 phase …